School of Medicine
Showing 1-10 of 26 Results
Ernest and Amelia Gallo Family Professor and Professor of Pediatrics and of Medicine
Current Research and Scholarly Interests Recent clinical studies, by us and others, have demonstrated that T cell based immunotherapy can eradicate cancers resistant to all other available therapies. Our program creates, develops and optimizes genetically engineered T cells to treat cancer. We link the bench with the bedside, developing novel therapies for early phase testing in clinical trials, while simultaneously conducting intensive studies on clinical samples obtained from patients treated on immunotherapy trials.
Sean Mackey, M.D., Ph.D.
Redlich Professor, Professor of Anesthesiology, Perioperative, and Pain Medicine and, by courtesy, of Neurology at the Stanford University Medical Center
Current Research and Scholarly Interests Multiple NIH funded projects to characterize CNS mechanisms of human pain. Comparative effectiveness of cognitive behavioral therapy and chronic pain self-management within the context of opioid reduction (PCORI funded). Single session pain catastrophizing treatment: comparative efficacy & mechanisms (NIH R01). Development and implementation of an open-source learning healthcare system, CHOIR (http://choir/stanford.edu), to optimize pain care and innovative research in real-world patients.
Professor (Research) of Microbiology and Immunology
Current Research and Scholarly Interests I'm interested in immune monitoring of T cell responses to chronic pathogens and cancer, and the correlation of T cell response signatures with disease protection.
Ravindra Majeti MD, PhD
Professor of Medicine (Hematology)
Current Research and Scholarly Interests The Majeti lab focuses on the molecular/genomic characterization and therapeutic targeting of leukemia stem cells in human hematologic malignancies, particularly acute myeloid leukemia (AML). Our lab uses experimental hematology methods, stem cell assays, genome editing, and bioinformatics to define and investigate drivers of leukemia stem cell behavior. As part of these studies, we have led the development and application of robust xenotransplantation assays for human hematopoietic cells.
Assistant Professor of Pediatrics (Hematology/Oncology) at the Stanford University Medical Center
Bio Robbie Majzner is an Assistant Professor of Pediatrics in the Division of Hematology and Oncology. After graduating with a BA from Columbia University, Dr. Majzner attended Harvard Medical School, where he developed an interest in pediatric oncology. He completed his residency training in pediatrics at New York Presbyterian-Columbia and fellowship training in pediatric hematology-oncology at Johns Hopkins and the National Cancer Institute. During his fellowship, he cared for some of the first pediatric patients to receive CD19 chimeric antigen receptor (CAR) T cells, children with B cell acute lymphoblastic leukemia (B-ALL) who often had no other therapeutic option. Witnessing the success of CAR T cells in these patients drove Dr. Majzner to the laboratory, where he focuses on extending the use of CAR T cells to solid tumors. He has generated and optimized novel receptors to recognize antigens over-expressed on pediatric solid tumors such as GD2 (Mount/Majzner et al., Nature Medicine, 2018) B7-H3 (Majzner et al., Clinical Cancer Research, 2019), and ALK (Walker/Majzner et al., Molecular Therapy, 2017). Current work focuses on imparting multi-specificity to CAR T cells and optimizing these receptors to enhance their efficacy when the amount of target (antigen density) is limiting (Majzner et al., Cancer Discovery, 2020). By drawing on state of the art bioengineering techniques, the Majzner Laboratory focuses on enhancing the potency and specificity of CAR T cells for children with cancer.
Clinically, Dr. Majzner cares for all patients with neuroblastoma at the Lucile Packard Children's Hospital and has a specific interest in bringing novel immunotherapies to clinical trials for these patients and those with other solid tumors. He is board certified in pediatrics and pediatric hematology-oncology.
Associate Professor (Research) of Radiology (Cancer Early Detection-Canary Center)
Current Research and Scholarly Interests The Mallick Lab is focused on using integrative, multi-omic approaches to model the processes that govern cellular dynamics and to use those models to discover cancer biomarkers and molecular mechanisms.
M. Peter Marinkovich, MD
Associate Professor of Dermatology
Current Research and Scholarly Interests The Marinkovich lab studies the function of epithelial extracellular matrix molecules, including integrins, collagens and laminins in epithelial development and carcinoma progression. We apply our discoveries in this area towards development of molecular therapies for carcinomas, hair disease and inherited epithelial adhesive disorders.
Professor of Surgery (Abdominal Transplantation)
Current Research and Scholarly Interests Host-Pathogen interactions; EBV B cell lymphomas; pathways of immune evasion in the growth and survival of EBV B cell lymphomas; mechanisms of graft rejection and tolerance induction; stem cell and solid organ transplantation.
Suleiman Alfred Massarweh
Current Research and Scholarly Interests My work is focused in investigating mechanisms of endocrine resistance in ER-positive breast cancer and novel clinical trial designs of combined ER and targeted therapeutics. Primary areas of investigation are in metastatic disease and preoperative clinical trials.
Additional areas of interest include breast cancer in young women, in men, and breast cancer diagnosed during pregnancy.
Tarik F. Massoud, MD, PhD
Professor of Radiology (Neuroimaging and Neurointervention) at the Stanford University Medical Center
Current Research and Scholarly Interests My current interests are in molecular and translational imaging of the brain especially in neuro-oncology and cerebrovascular diseases, experimental aspects of neuroimaging, clinical neuroradiology, neuroradiological anatomy, and research education and academic training of radiologists and scientists.